Physician profile
Mary E Connell
NPI 1396194403
$2,883.56
in general payments reported to CMS, 2019-2025
25 companies · $643 in 2025
The $643 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $169 · 2021: $362 · 2022: $361 · 2023: $686 · 2024: $662 · 2025: $643.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,992.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,991.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $513.60 | 2021-2025 | Otezla, Repatha, Enbrel |
| Ucb, INC. | $426.46 | 2021-2025 | Cimzia, Bimzelx |
| Mylan Specialty L.P. | $280.86 | 2021-2024 | Yupelri |
| Lilly USA, LLC | $266.54 | 2021-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $244.77 | 2021-2025 | Farxiga, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $168.71 | 2022-2025 | |
| Viatris Specialty LLC | $111.59 | 2025 | Yupelri |
| Teva Pharmaceuticals USA, INC. | $106.16 | 2019 | |
| Novo Nordisk INC | $105.46 | 2022-2024 | Rybelsus, Ozempic |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $94.33 | 2025 | Caplyta |
| Amarin Pharma, INC. | $82.51 | 2021-2022 | |
| Exact Sciences Corporation | $63.89 | 2023-2025 | Cologuard Collection Kit |
| Alkermes, INC. | $62.37 | 2019 | |
| Axsome Therapeutics, INC. | $40.27 | 2025 | Auvelity |
| Organon LLC | $37.07 | 2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $36.24 | 2025 | Spravato, Invega Sustenna |
| E.R. Squibb & Sons, L.L.C. | $34.90 | 2023 | Eliquis |
| Dexcom, INC. | $33.76 | 2023-2024 | Dexcom G6 Transmitter |
| Abbvie INC. | $32.96 | 2024 | |
| Paratek Pharmaceuticals, INC. | $31.54 | 2022-2023 | Nuzyra |
| Grifols USA, LLC | $30.94 | 2021-2024 | Prolastin-C Liquid |
| Mallinckrodt Hospital Products INC. | $29.62 | 2024 | Acthar |
| Pfizer INC. | $19.07 | 2021 | |
| Novartis Pharmaceuticals Corporation | $15.35 | 2025 | |
| Sumitomo Pharma America, INC. | $14.59 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Connell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.